“It’s been an exciting time in the treatment of AML,” said Mikkael Sekeres, M.D., M.S., Chief of the Division of Hematology at Sylvester, and senior author on the article. “The time was ripe for an update on the biology of AML and the treatment approaches that we've adopted since the approval of these drugs,” he added.